CAH

• The new facility replaces Cardinal Health's existing 364-day and five-year revolving credit facilities and its $1.0 billion receivables sale facility program.
• The Credit Agreement includes a financial covenant requiring a Consolidated Net Leverage Ratio of no greater than 4.00 to 1.00 as of the last day of any fiscal quarter.
• The terminated facilities included a $2.0 billion five-year credit agreement (dated February 27, 2023) and a $1.0 billion 364-day credit agreement (dated October 7, 2025).
• No penalties were incurred as a result of the terminations; the new facility will be used for general corporate purposes.

1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits

• Fourth quarter non-GAAP diluted EPS increased 40% to $2.91, including a one-time $0.31 benefit from IEEPA tariff refund recognition.
• Fiscal year 2026 revenue increased 14% to $254.2 billion; non-GAAP diluted EPS increased 37% to $11.26.
• Fiscal year 2026 operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion.
• Company provides fiscal year 2027 non-GAAP EPS guidance of $12.40 to $12.60, representing 13% to 15% growth.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• On August 4, 2026, Cardinal Health appointed Anita Zielinski as Chief Accounting Officer, effective November 5, 2026.
• Mary Scherer will continue as Chief Accounting Officer until November 5, 2026, when Zielinski succeeds her.
• Zielinski previously served as interim CFO and Chief Accounting Officer at Baxter International and held finance roles at Sysco and Ernst & Young.
• She will receive a $750,000 cash sign-on bonus and $1,000,000 in time-vesting restricted share units vesting over three years.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• GAAP operating earnings decreased 30% to $509 million, and GAAP diluted EPS decreased 20% to $1.69, reflecting a $184 million pre-tax goodwill impairment in the Navista & ION reporting unit.
• Non-GAAP operating earnings increased 18% to $956 million, and non-GAAP diluted EPS increased 35% to $3.17.
• The company raised and narrowed fiscal year 2026 non-GAAP EPS guidance to $10.70-$10.80, and raised adjusted free cash flow guidance to $3.3-$3.7 billion.
• Cardinal Health completed an additional $250 million share repurchase, bringing fiscal 2026 repurchases to $1.0 billion, and reduced debt with a $100 million term loan payment ahead of schedule.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Gregory B. Kenny notified Cardinal Health of his retirement from the Board and as Board Chair, effective March 20, 2026.
• Patricia A. Hemingway Hall, a current director since 2013, was appointed Board Chair effective immediately.
• The Company will release third quarter fiscal 2026 earnings on April 30, 2026.
• The Company remains confident in its fiscal 2026 outlook.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Mary Scherer, Senior Vice President and Chief Accounting Officer, notified Cardinal Health of her intent to retire in February 2027.
• Scherer will continue as Chief Accounting Officer until her successor is onboarded to ensure a smooth transition.
• The notification was made on March 2, 2026, and the 8-K was filed on March 5, 2026.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• GAAP diluted EPS increased 19% to $1.97; non-GAAP diluted EPS increased 36% to $2.63.
• GAAP operating earnings rose 29% to $707 million; non-GAAP operating earnings rose 38% to $877 million.
• The company raised fiscal year 2026 non-GAAP EPS guidance to $10.15–$10.35, representing 23%–26% growth.
• Completed $750 million year-to-date share repurchases, including a $375 million accelerated repurchase in Q2.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Cardinal Health increased its fiscal 2026 non-GAAP diluted EPS guidance to at least $10.00, up from the prior range of $9.65 to $9.85.
• Cardinal Health confirmed successful transition of manufacturer distribution service agreements for all branded drugs impacted by the 2026 Medicare Drug Price Negotiation Program.
• The at-Home Solutions business introduced ContinuCare™ Pathway and enrolled Publix's nearly 1,400 pharmacies, expanding the program to over 11,000 retail and grocery pharmacies.
• The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, and will provide further details on its Q2 earnings call on February 5, 2026.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits